TheraPPI Bioscience, a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases and inflammation
Products, services, technology
TheraPPI’s two first programs target a protein interaction discovered by the founder team. Our first oncology program revolutionizes RAS-MAPK targeting: the new mode of action leverages 3 mechanisms with direct cancer cell killing, no cancer resistance and activation of anti-tumor immune response.
- https://tppibio.com/
- Luc Otten
Some insights
TheraPPI Bioscience develops novel drugs that modify protein interactions to combat cancer drug resistance and to cure rare diseases
We are proud to be at the cutting edge of developing drugs that target protein interactions for better patient health.
The management team has a proven expertise in several key areas for a start-up: identification of novel therapeutic targets, discovery of PPI inhibitors, translational and early clinical development in oncology, and experience in finance.
We look for talents in drug discovery.
Enthusiasts and resilients
Multiple interactions with most players of the Swiss biotech ecosystem